These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 18449827)

  • 1. The face of HIV and AIDS: can we erase the stigma?
    Kavouni A; Catalan J; Brown S; Mandalia S; Barton SE
    AIDS Care; 2008 Apr; 20(4):485-7. PubMed ID: 18449827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Injectable poly-L-lactic acid (Sculptra): technical considerations in soft-tissue contouring.
    Lam SM; Azizzadeh B; Graivier M
    Plast Reconstr Surg; 2006 Sep; 118(3 Suppl):55S-63S. PubMed ID: 16936545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy.
    Burgess CM; Quiroga RM
    J Am Acad Dermatol; 2005 Feb; 52(2):233-9. PubMed ID: 15692467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy.
    Moyle GJ; Brown S; Lysakova L; Barton SE
    HIV Med; 2006 Apr; 7(3):181-5. PubMed ID: 16494632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of HIV lipoatrophy and lipoatrophy of aging with poly-L-lactic acid: a prospective 3-year follow-up study.
    Levy RM; Redbord KP; Hanke CW
    J Am Acad Dermatol; 2008 Dec; 59(6):923-33. PubMed ID: 19022099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly-L-lactic acid.
    Perry CM
    Am J Clin Dermatol; 2004; 5(5):361-6; discussion 367-8. PubMed ID: 15554738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Polylactic acid injections: usefullness for the treatment of facial lipoatrophy in HIV+ patients under tritherapy].
    Piquet M; Brignol L; Chatelain B; Rey D; Ricbourg B; Meyer C
    Rev Stomatol Chir Maxillofac; 2007 Dec; 108(6):496-504. PubMed ID: 17675198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep subcutaneous application of poly-L-lactic acid as a filler for facial lipoatrophy in HIV-infected patients.
    Borelli C; Kunte C; Weisenseel P; Thoma-Greber E; Korting HC; Konz B
    Skin Pharmacol Physiol; 2005; 18(6):273-8. PubMed ID: 16113597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly-L-lactic acid injection for HIV-associated facial lipoatrophy: treatment principles, case studies, and literature review.
    Kates LC; Fitzgerald R
    Aesthet Surg J; 2008; 28(4):397-403. PubMed ID: 19083552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semipermanent filler treatment of HIV-positive patients with facial lipoatrophy: long-term follow-up evaluating MR imaging and quality of life.
    van Rozelaar L; Kadouch JA; Duyndam DA; Nieuwkerk PT; Lutgendorff F; Karim RB
    Aesthet Surg J; 2014 Jan; 34(1):118-32. PubMed ID: 24334306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soft-tissue augmentation and the role of poly-L-lactic acid.
    Vleggaar D
    Plast Reconstr Surg; 2006 Sep; 118(3 Suppl):46S-54S. PubMed ID: 16936544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient satisfaction and duration of effect with PLLA: a review of the literature.
    Palm MD; Goldman MP
    J Drugs Dermatol; 2009 Oct; 8(10 Suppl):s15-20. PubMed ID: 19891117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retreatment with injectable poly-l-lactic acid for HIV-associated facial lipoatrophy: 24-month extension of the Blue Pacific study.
    Mest DR; Humble GM
    Dermatol Surg; 2009 Feb; 35 Suppl 1():350-9. PubMed ID: 19207325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poly-l-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up.
    Carey D; Baker D; Petoumenos K; Chuah J; Rogers GD; Watson J; Cooper DA; Emery S; Carr A;
    HIV Med; 2009 Mar; 10(3):163-72. PubMed ID: 19245538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly-L-lactic acid for treating HIV-associated facial lipoatrophy: a review of the clinical studies.
    Barton SE; Engelhard P; Conant M
    Int J STD AIDS; 2006 Jul; 17(7):429-35. PubMed ID: 16820069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of poly-L-lactic acid in HIV lipoatrophy and lipoatrophy of aging.
    Hanke CW; Redbord KP
    J Drugs Dermatol; 2007 Feb; 6(2):123-8. PubMed ID: 17373169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Polylactic acid injections (Newfill) in the treatment of facial lipodystrophy in HIV-positive patients].
    Bodokh I; Simonet P
    Ann Dermatol Venereol; 2006 May; 133(5 Pt 1):429-32. PubMed ID: 16760828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection.
    Moyle GJ; Lysakova L; Brown S; Sibtain N; Healy J; Priest C; Mandalia S; Barton SE
    HIV Med; 2004 Mar; 5(2):82-7. PubMed ID: 15012646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of poly-L-lactic acid (New-Fill®) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients.
    Duracinsky M; Leclercq P; Herrmann S; Christen MO; Dolivo M; Goujard C; Chassany O
    BMC Infect Dis; 2014 Sep; 14():474. PubMed ID: 25178390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly-L-lactic acid: a perspective from my practice.
    Sadick NS
    J Cosmet Dermatol; 2008 Mar; 7(1):55-60. PubMed ID: 18254813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.